Alzamend Neuro Inc (ALZN)

04:59 AM

Alzamend Neuro Announces Bylaws Amendment and New Stock Series - Investing.com

04:59 AM

Feb 28, 2025

Alzamend Neuro inks deal for equity securities sale By Investing.com - Investing.com South Africa

Feb 28, 2025

Feb 28, 2025

Alzamend Neuro inks deal for equity securities sale - Investing.com

Feb 28, 2025

Feb 28, 2025

Alzamend Neuro stock hits 52-week low at $0.81 amid sharp decline - Investing.com India

Feb 28, 2025

Feb 25, 2025

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital - The Manila Times

Feb 25, 2025

Feb 25, 2025

Can Alzamend's New Lithium Formulation Eliminate Monitoring Requirements? Phase II Trial Set for 2025 - StockTitan

Feb 25, 2025

Feb 25, 2025

EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 - Yahoo Finance

Feb 25, 2025

Feb 21, 2025

EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels - AOL

Feb 21, 2025

Feb 19, 2025

Alzamend Neuro stock hits 52-week low at $1.05 amid challenges - Investing.com

Feb 19, 2025

Feb 19, 2025

Alzamend Neuro Announces Completion Of A Novel Head Coil By Tesla For Measuring Brain Structure Lithium Levels In Five Upcoming Phase Ii Clinical Trials At Massachusetts General Hospital - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

Alzamend Neuro stock hits 52-week low at $1.05 amid challenges By Investing.com - Investing.com South Africa

Feb 19, 2025

Feb 19, 2025

Alzamend Neuro announces head coil for lithium studies By Investing.com - Investing.com South Africa

Feb 19, 2025

Feb 19, 2025

Alzamend Neuro announces head coil for lithium studies - Investing.com India

Feb 19, 2025

Feb 19, 2025

ALZNAlzamend Neuro Inc Latest Stock News & Market Updates - StockTitan

Feb 19, 2025

Feb 19, 2025

Alzamend Neuro announces completion of head coil by Tesla Dynamic Coils - TipRanks

Feb 19, 2025

Feb 19, 2025

Alzamend Neuro, Inc. Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Marketscreener.com

Feb 19, 2025

Feb 12, 2025

Alzamend Neuro stock hits 52-week low at $1.05 amid sharp decline - Investing.com Canada

Feb 12, 2025

Feb 01, 2025

Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher - MSN

Feb 01, 2025

Jan 29, 2025

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World

Jan 29, 2025

Jan 23, 2025

Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Jan 23, 2025

Jan 15, 2025

Alzamend Neuro to Present at the Sequire Investor Summit - Business Wire

Jan 15, 2025

Jan 15, 2025

Alzamend Neuro CEO to Present Five Phase II Trial Plans at Sequire Investor Summit - StockTitan

Jan 15, 2025

Dec 18, 2024

Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo - Business Wire

Dec 18, 2024

Dec 17, 2024

Alzamend Neuro (NASDAQ:ALZN) Price Target Cut to $32.00 by Analysts at Ascendiant Capital Markets - Defense World

Dec 17, 2024

Dec 15, 2024

Alzamend Neuro Reports Strong Financial Results and Clinical Program Updates - Defense World

Dec 15, 2024

Dec 13, 2024

Alzamend Neuro says net cash gained by financing activity $8.3M - Yahoo Finance

Dec 13, 2024

Dec 13, 2024

Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com

Dec 13, 2024

Dec 12, 2024

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs - Business Wire

Dec 12, 2024

Dec 12, 2024

Alzamend Neuro Secures $25M Financing Deal, Advances Alzheimer's Drug Pipeline Amid Financial Turnaround - StockTitan

Dec 12, 2024

Dec 11, 2024

Alzamend Neuro Inc. (ALZN) reports earnings - Quartz

Dec 11, 2024

Dec 03, 2024

Alzamend Neuro stock hits 52-week low at $1.24 amid market challenges - Investing.com Nigeria

Dec 03, 2024

Nov 19, 2024

Alzamend reports promising results for brain-targeted lithium therapy - Investing.com India

Nov 19, 2024

Nov 19, 2024

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice - Business Wire

Nov 19, 2024

Nov 19, 2024

EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential - Yahoo Finance

Nov 19, 2024

Nov 15, 2024

Alzamend Neuro stock hits 52-week low at $1.39 amid sharp decline - Investing.com

Nov 15, 2024

Oct 24, 2024

Alzamend Neuro sets trial dosage for AL001 lithium therapy - Alzheimer's News Today

Oct 24, 2024

Oct 17, 2024

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s - BioSpace

Oct 17, 2024

Oct 16, 2024

Alzamend Neuro advances Alzheimer's treatment with new lithium dose - Investing.com

Oct 16, 2024

Oct 16, 2024

Alzamend Neuro advances Alzheimer's treatment with new lithium dose By Investing.com - Investing.com South Africa

Oct 16, 2024

Oct 16, 2024

EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's - Yahoo Finance

Oct 16, 2024

Oct 15, 2024

Alzamend Neuro Inc (ALZN) receives a Buy rating from Ascendiant Capital Markets - Knox Daily

Oct 15, 2024

Oct 15, 2024

Alzamend Neuro Inc (ALZN) Performance and Fundamentals Dashboard tells a completely different story - SETE News

Oct 15, 2024

Oct 15, 2024

Alzamend Neuro Inc (ALZN-Q) QuotePress Release - The Globe and Mail

Oct 15, 2024

Oct 15, 2024

Alzamend Neuro regains Nasdaq compliance with equity rule By Investing.com - Investing.com UK

Oct 15, 2024

Oct 15, 2024

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - StockTitan

Oct 15, 2024

Oct 13, 2024

Alzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42 - MSN

Oct 13, 2024

Oct 10, 2024

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference - Barchart

Oct 10, 2024